Anti-Human C3aR Monoclonal Antibody (clone 17) -100 µg - Creative Biolabs
Book a Meeting

Anti-Human C3aR Monoclonal Antibody (clone 17) -100 µg (CAT#: CB-P192-AB) Datasheet

Product Type
Antibody
Description
The monoclonal antibody 17 reacts with the human C3a receptor. The monoclonal antibody 17 is also referred to as clone hC3aRZ8 in the literature.
In the process of complement activation, C3a receptor acts as the cell surface receptor of anaphylatoxin C3a. C3a is the C-terminal 77 amino acid cleavage product of C3's α chain, but it has no effect on C3a-desArg. All cellular responses to C3a are specifically mediated through interaction with membrane-bound C3a receptors (seven transmembrane GTP-binding protein-coupled receptors of the rhodopsin supergene family). 54 kDa C3a receptors are widely distributed in myeloid cells, surrounding tissues and central nervous system. The expression of C3aR has been confirmed on neutrophils, monocytes, eosinophils, astrocytes, neurons and glial cells, and increased under inflammatory conditions. Even after stimulation, C3aR expression was not detected on lymphocytes and tonsil B cells.
Disease
Infectious diseases, Nephrology
Size
100 µg
Species
Human
Host
Mouse
Clonality
Monoclonal
Isotype
Mouse IgG2b
Clone Number
17
Buffer
PBS, containing 0.02% sodium azide and 1% bovine serum albumin.
Application
Flow cytometry, Frozen sections
Application Notes
For flow cytometry and immunohistochemistry, the diluent to be used depends on the detection system used. It is recommended that users test reagents and determine their own optimal dilution. The typical initial working dilution is 1:50.
Storage Instructions
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Target
C3aR
Alternative Names
C3AR1; AZ3B; C3AR; HNFAG09; complement component 3a receptor 1; complement C3a receptor 1

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany